Glukokortikoid Reseptör Geni (NR3C1) ve Meme Kanserinde Rolü
Meme kanseri oldukça heterojen bir kanser olup, kanserin orijinine bağlı olarak adenokarsinom,duktal, lobular ve meme ucu karsinom olarak sınıflandırılabilir. Histolojik tiplendirme dışındameme kanseri östrojen reseptör (ER), progesteron reseptör (PR) ve epidermal büyüme faktörüreseptör 2 (ERBB2/HER2) gibi düzenleyicilerdeki mutasyonlar ile ayrıca moleküler olaraksınıflandırılabilir. Glukokortikoidler (GC) meme kanseri dahil birçok hastalığın tedavisindekullanılmaktadır. GC’ler kemoterapinin yan etkilerini azaltmak ve normal dokuyu memekanserinde genotoksik ilaçların uzun süreli etkilerine karşı korumak için sıklıkla bir adjuvantedavi olarak uygulanır. GC’lerin etkileri genellikle glukokortikoid reseptör (GR) aracılığıile gerçekleşir. GR etkilerinin anlaşılması meme kanseri tedavisindeki potansiyel ilgisinintartışılmasında önemli olacaktır. Bu derlemenin amacı, meme kanserinin gelişmesi veilerlemesinde GR’nin etkilerini tanımlamaktır.
___
- 1. Edge SB, Byrd DR, Compton CC (Eds.), AJCC
Cancer Staging Manual, 7th ed., Springer, New
York, NY, Breast 2010; pp. 347-376.
2. Sorlie T, Tibshirani R, Parker J, et al. Repeated
observation of breast tumor subtypes in independent
gene expression data sets, Proc Natl Acad Sci 2003;
100: 8418-8423.
3. Lecoq L, Vincent P, Lavoie-Lamoureux A, et al.
Genomic and non-genomic effects of dexamethasone
on equine peripheral blood neutrophils. Vet
Immunol Immunopathol 2009; 15: 126-31.
4. Moutsatsou P, Papavassiliou AG. The
glucocorticoid receptor signalling in breast cancer.
J Cell Mol Med 2008; 12: 145-63.
5. Simoncini T, Genazzani AR. Non-genomic
actions of sex steroid hormones. Eur J Endocrinol
2003; 148: 281-92.
6. Duma D, Jewell CM, Cidlowski JA. Multiple
glucocorticoid receptor isoforms and mechanisms
of post-translational modification. J Steroid
Biochem Mol Biol 2006; 102: 11-21.
7. Sundahl N, Clarisse D, Bracke M, et al. eCollection
2016. Selective glucocorticoid receptoractivating
adjuvant therapy in cancer treatments.
Oncoscience 2016; 3: 188-202.
8. McNamara KM, Kannai A, Sasano H. Possible
roles for glucocorticoid signalling in breast cancer.
Mol Cell Endocrinolol 2018; 466: 38-50.
9. Beato M, Sanchez-Pacheco A. Interaction of
steroid hormone receptors with the transcription
initiation complex. Endocr Rev 1996;17: 587-609.
10. Hollenberg, SM, Weinberger C, et al. Primary
structure and expression of a functional human
glucocorticoid receptor cDNA. Nature 1985; 318:
635-641.
11. Encio IJ, Detera-Wadleigh SD. The genomic
structure of the human glucocorticoid receptor. J
Biol Chem 1991; 266: 7182-7188.
12. Oakley RH, Sar M, Cidlowski JA. The human
glucocorticoid receptor beta isoform. Expression,
biochemical properties, and putative function. J
Biol Chem 1996; 271: 9550-9559.
13. Kino T, Manoli I, Kelkar S, et al. Glucocorticoid
receptor (GR) has intrinsic, GR-independent
transcriptional activity. Biochem Biophys Res
Commun 2009; 381: 671-675.
14. K. Hecht J, Carlstedt-Duke P, Stierna J,
et al. Evidence that the beta-isoform of the
human glucocorticoid receptor does not act as a
phsiologically significant repressor, J Biol Chem
1997; 272: 26659.
15. Yudt MR, Jewell CM, Bienstock RJ, et al.
Molecular origins fort he dominant negative
function of human glucocorticoid receptor beta.
Mol Cell Biol 2003; 23: 4319.
16. Oakley RH, Jewell CM, Yudt MR, et al.
The dominant negative activity of the human
glucocorticoid receptor beta isoform. Specificity
and mechanisms of action J Biol Chem 1999; 274:
27857.
17. Goulding NJ. The molecular complexityof
glucocorticoid actions in inflammation – a four-ring
circus. Curr Opin Pharmacol 2004; 4: 629-636.
18. Rivers C, Levy A, Hancock J, et al. Insertion
of an amino acid in the DNA-binding domain of
the glucocorticoid receptor as a result of alternative
splicing, J Clin Endocrinol Metab 1999; 84: 4283.
19. Hollenberg SM, Evans RM. Multiple and
cooperative transactivation domains of the human
glucocorticoid receptor. Cell 1988; 55: 899-906.
20. Gross KL, Cidlowski JA. Tissue-specific
glucocorticoid action: a family affair, Trends
Endocrinol Metab 2008; 19: 331-339.
21. Adcock IM, Ito K. Molecular mechanisms of
corticosteroid actions, Monaldi Arch Chest Dis
2000; 55: 256.
22. Morishima Y, Murphy PJ, Li DP, et al.
Stepwise assembly of a glucocorticoid receptor
hsp90 heterocomplex resolves two sequential ATPdependent
events involving first hsp70 and then
hsp90 in opening of the steroid binding pocket. J
Biol Chem 2000; 275:18054.
23. Schaaf MJ, Cidlowski JA. Molecular
determinants of glucocorticoid receptor mobility in
living cells: the importance of ligand affinity. Mol
Cell Biol 2003; 23: 1922-1934.
24. Holaska JM, Black BE, Rastinejad F, et al. Ca2+
dependent nuclear export mediated by calreticulin.
Mol Cell Biol 2002; 22: 6286-6297.
25. Kino T, Souvatzoglou E, De Martino MU,
et al. Protein 14-3-3σ interacts with and favors
cytoplasmic subcellular localization of the
glucocorticoid receptor, acting as a negative
regulator of the glucocorticoid signaling pathway.
J Biol Chem 2003; 278: 25651-25656.
26. Boldizar F, Talamber G, Szabo M, et al.
Emerging pathways of non-genomic glucocorticoid
(GC) signalling in T cells. Immunobiology 2010;
215: 521-526.
27. Z. Wang J, Frederick MJ. Garabedian,
Deciphering the phosphorylation ―code‖ of the
glucocorticoid receptor in vivo. J Biol Chem 2002;
277: 26573.
28. Adcock IM, Caramori G. Cross-talk between
pro-inflammatory transcription factors and
glucocorticoids, Immunol Cell Biol 2001; 79: 376.
29. Kino T, Chrousos GP. Tissue-specific
glucocorticoid resistancehypersensitivity syndromes:
multifactorial states of clinical importance. J
Allergy Clin Immunol 2002; 109: 609-613.
30. Barnes PJ, Adcock IM. How do corticosteroids
work in asthma? Ann Intern Med 2003; 139: 59-370.
31. Kinyamu HK, Chen J, Archer TK. Linking
the ubiquitin– proteasome pathway to chromatin
remodeling/modification by nuclear receptors. J
Mol Endocrinol 2005; 34: 281-297.
32. Le DY, Mincheneau N, Le GP, et al. Potentiation
of glucocorticoid receptor transcriptional activity by
sumoylation. Endocrinology 2002; 143: 3482-3489.
33. Nader N, Chrousos GP, Kino T. Circadian
rhythm transcription factor CLOCK regulates
the transcriptional activity of the glucocorticoid
receptor by acetylating its hinge region lysine
cluster: potential physiological implications. Faseb
J 2009; 23: 1572-1583.
34. Galliher-Beckley AJ, Williams JG, Collins JB,
et al. Glycogen synthase kinase 3 beta-mediated
serine phosphorylation of the human glucocorticoid
receptor redirects gene expression profiles. Mol
Cell Biol 2008; 28: 7309-7322.
35. Seckl JR. Prenatal glucocorticoids and long-term
programming. Eur J Endocrinol 2004; 151: 49-62.
36. Horwitz KB, Costlow ME, McGuire WL. MCF-
7; a human breast cancer cell line with estrogen,
androgen, progesterone, and glucocorticoid
receptors. Steroids 1975; 26:785-795.
37. Moran TJ, Gray S, Mikosz CA, et al. The
glucocorticoid receptor mediates a survival signal
in human mammary epithelial cells. Cancer Res
2000; 60: 867-872.
38. Mikosz CA, Brickley DR, Sharkey MS, et al.
Glucocorticoid receptor-mediated protection from
apoptosis is associated with induction of the serine/
threonine survival kinase gene, sgk-1. J Biol Chem
2001; 276: 16649-16654.
39. Herr I, Pfitzenmaier J. Glucocorticoid use
in prostate cancer and other solid tumours:
implications for effectiveness of cytotoxic treatment
and metastases. Lancet Oncol 2006; 7: 425-430.
40. Wu W, Chaudhuri S, Brickley DR, et al.
Microarray analysis reveals glucocorticoidregulated
survival genes that are associated with
inhibition of apoptosis in breast epithelial cells.
Cancer Res 2004; 64: 1757-1764.
41. Sherlock P, Hartmann WH. Adrenal steroids
and the pattern of metastases of breast cancer.
JAMA 1962; 181: 313-317
42. Pang D, Kocherginsky M, Krausz T, et al.
Dexamethasone decreases xenograft response
to Paclitaxel through inhibition of tumor cell
apoptosis. Cancer Biol Ther 2006; 5: 933-940.
43. Skor MN, Wonder EL, Kocherginsky M, et
al. Glucocorticoid receptor antagonism as a novel
therapy for triple-negative breast cancer. Clin
Cancer Res 2013; 19: 6163-6172.
44. Pan D, Kocherginsky M, Conzen SD. Activation
of the glucocorticoid receptor is associated with
poor prognosis in estrogen receptor-negative breast
cancer. Cancer Res 2011; 71: 6360-6370
45. Spiegel D, Butler LD, Giese-Davis J, et al.
Effects of supportive-expressive group therapy on
survival of patients with metastatic breast cancer –
a randomized prospective trial. Cancer 2007; 110:
1130-1138.
46. Zhang C, Wenger T, Mattern J, et al. Clinical
and mechanistic aspects of glucocorticoid induced
chemotherapy resistance in the majority of solid
tumors. Cancer Biol Ther 2007; 6: 278-287.
47. Park J, Euhus DM, Scherer PE. Paracrine
and endocrine effects of adipose tissue on cancer
development and progression. Endocr Rev 2011;
32: 550-570.
48. Masuzaki H, Paterson J, Shinyama H, et al.
A transgenic model of visceral obesity and the
metabolic syndrome. Science 2001; 294: 2166-
2170.
49. Law ME, Corsino PE, Jahn SC, et al.
Glucocorticoids and histone deacetylase inhibitors
cooperate to block the invasiveness of basal-like
breast cancer cells through novel mechanisms.
Oncogene 2013; 32:1316-1329.
50. Yano A, Fujii Y, Iwai A, et al. Glucocorticoids
suppress tumor angiogenesis and in vivo growth
of prostate cancer cells, Clin Cancer Res 2006; 12:
3003-3009.
51. Lin KT, Yeh YM, Chuang CM, et
al. Glucocorticoids mediate induction of
microRNA-708 to suppress ovarian cancer
metastasis through targeting Rap1B, Nat Commun
2015; 6: 5917.
52. Lien HC, Lu YS, Cheng AL, et al. Differential
expression of glucocorticoid receptor in human
breast tissues and related neoplasms. J Pathol 2006;
209: 317-327.
53. Nesset KA, Perri AM, Mueller CR. Frequent
promoter hypermethylation and expression
reduction of the glucocorticoid receptor gene in
breast tumors. Epigenetics 2014; 9: 851-859.
54. Lietzen LW, Ahern T, Christiansen P, et al.
Glucocorticoid prescriptions and breast cancer
recurrence: a Danish nationwide prospective cohort
study. Ann Oncol 2014; 25: 2419-2425.
55. Sorensen GV, Cronin-Fenton DP, Sorensen
HT, et al. Use of glucocorticoids and risk of breast
cancer: a Danish population-based case-control
study. Breast Cancer Res 2012; 14: 21-30.